These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 34818092

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 3. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.
    Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Maher TM.
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S17-S24. PubMed ID: 28287347
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P, Schwarzkopf L, Schwettmann L, Ruhnke T, Trudzinski F, Kreuter M.
    Respir Res; 2021 Oct 19; 22(1):268. PubMed ID: 34666765
    [Abstract] [Full Text] [Related]

  • 6. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, Liu Y, Lopez-Gitlitz A, Francis P, Bevans KB, Fizazi K.
    J Manag Care Spec Pharm; 2023 Jul 19; 29(7):758-768. PubMed ID: 37404070
    [Abstract] [Full Text] [Related]

  • 7. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol; 2023 Jul 19; 210(1):224-226. PubMed ID: 37119051
    [Abstract] [Full Text] [Related]

  • 8. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
    Lee CT, Hao W, Burg CA, Best J, Kolenic GE, Strek ME.
    Respir Res; 2024 Jun 21; 25(1):255. PubMed ID: 38907239
    [Abstract] [Full Text] [Related]

  • 9. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.
    Int J MS Care; 2016 Jun 21; 18(6):314-323. PubMed ID: 27999526
    [Abstract] [Full Text] [Related]

  • 10. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M, DeYoung K, Kong AM.
    BMC Pulm Med; 2020 Jul 11; 20(1):188. PubMed ID: 32652979
    [Abstract] [Full Text] [Related]

  • 11. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
    Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin NN, Devercelli G, Coultas DB.
    J Manag Care Spec Pharm; 2016 Apr 11; 22(4):414-23. PubMed ID: 27023695
    [Abstract] [Full Text] [Related]

  • 12. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
    Kelly BT, Thao V, Dempsey TM, Sangaralingham LR, Payne SR, Teague TT, Moua T, Shah ND, Limper AH.
    BMC Pulm Med; 2021 Jul 17; 21(1):239. PubMed ID: 34273943
    [Abstract] [Full Text] [Related]

  • 13. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis.
    Corral M, Chang E, Broder MS, Gokhale S, Reddy SR.
    J Comp Eff Res; 2020 Sep 17; 9(13):933-943. PubMed ID: 32851849
    [Abstract] [Full Text] [Related]

  • 14. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
    Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH.
    Am J Respir Crit Care Med; 2019 Jul 15; 200(2):168-174. PubMed ID: 31150266
    [Abstract] [Full Text] [Related]

  • 15. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M, Dalon F, Nolin M, Van Ganse E.
    Respir Res; 2021 May 04; 22(1):135. PubMed ID: 33947414
    [Abstract] [Full Text] [Related]

  • 16. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM, Pandey R, Fazioli K, Ollendorf DA, Carlson JJ.
    J Manag Care Spec Pharm; 2021 Aug 04; 27(8):1046-1055. PubMed ID: 34337994
    [Abstract] [Full Text] [Related]

  • 17. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
    Hozumi H, Miyashita K, Nakatani E, Inoue Y, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Suda T.
    Respir Res; 2024 Jul 31; 25(1):293. PubMed ID: 39085869
    [Abstract] [Full Text] [Related]

  • 18. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
    Dorey-Stein ZL, Shapiro W, Zhao H, Cordova FC, Criner GJ, Galli JA.
    Respir Med; 2021 Dec 31; 190():106599. PubMed ID: 34788735
    [Abstract] [Full Text] [Related]

  • 19. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.
    Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH.
    Ann Am Thorac Soc; 2021 Jul 31; 18(7):1121-1128. PubMed ID: 33465323
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia.
    Pandya BJ, Qi CZ, Garnham A, Yang H, Shah MV, Zeidan AM.
    J Manag Care Spec Pharm; 2021 Oct 31; 27(10):1469-1481. PubMed ID: 34595955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.